Realheart Artificial Heart Preserves Platelet Function
A new peer-reviewed study finds blood-compatible performance in the four-chamber artificial heart system.
Updated on Oct. 20, 2026 in Heart Disease
Live Poll
Are advancements in artificial heart technology making these devices safer for long-term use?
Researchers have published a peer-reviewed study in the journal Platelets demonstrating that the Realheart Total Artificial Heart preserves platelet functionality. The analysis shows no evidence of impaired clotting or platelet activation after circulation through the device.
Why it matters
Achieving blood compatibility is essential for the success of artificial heart systems in long-term clinical applications. This study indicates that the device design successfully minimizes damage to blood components during circulation.
A study published in the journal Platelets confirms that platelets maintain full responsiveness and integrity after passing through the four-chambered Realheart system. The research successfully ruled out device-induced impairment.
The players
Karolinska Institutet
This is a medical university in Sweden that serves as a global leader in clinical research and scientific innovation.
Realheart
This company specializes in the development of total artificial heart systems designed to mimic natural human cardiac function.
The details
The Karolinska Institutet research team assessed platelet integrity, activation status, and clotting functionality using multiple analytical methods under laboratory conditions. Findings confirm that the system successfully supports physiological blood flow while maintaining critical component performance.
Timeline
October 20, 2026: The peer-reviewed study was published in the journal Platelets.
The Big Picture
This study advances the field of mechanical circulatory support by aligning device testing with the ISO 10993 standards for biological evaluation of medical devices. It marks a critical verification step toward meeting the global safety requirements for long-term implantation.
This research suggests a future where artificial hearts may require less invasive management of blood-thinning medications for patients. Improved blood compatibility is a prerequisite for reducing potential side effects and enhancing quality of life for long-term recipients.
The takeaway
This study validates a key engineering milestone for the Realheart system regarding its interaction with human blood. These laboratory results offer a promising foundation for future clinical trials involving total artificial heart replacement.
Further reading
For additional context on cardiac innovations, visit the Heart Disease section.
Source note: This article includes information reported by News-Medical.
Live Poll
Are advancements in artificial heart technology making these devices safer for long-term use?
